SAN DIEGO, June 18, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the
Company has been invited to participate in and present at the BIO
Business Forum at the 2012 BIO International Convention, which is
being held June 18 – 21, 2012 in
Boston, MA. Brian M. Culley,
Chief Executive Officer of ADVENTRX, will present on Tuesday, June 19th at 9:30
a.m. EDT in the Celtics Room (104C) at the Boston Convention
& Exhibition Center.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
"We look forward to participating in the BIO Business Forum,
which will allow us to reach a global audience representing over 60
countries and to take advantage of the significant one-on-one
partnering and networking opportunities at the convention," stated
Mr. Culley. "We believe in ANX-188's potential as an
effective treatment for patients with sickle cell disease and are
pleased to have the opportunity to continue to share its story with
industry leaders and potential partners, particularly on
June 19th, which is designated by the
United Nations as World Sickle Cell Awareness Day."
About BIO
The Biotechnology Industry Organization (BIO) represents
more than 1,100 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across
the United States and in more than
30 other nations. The BIO International Convention is the largest
global event for the biotechnology industry and attracts the
biggest names in biotech, offers key networking and partnering
opportunities, and provides insights and inspiration on the major
trends affecting the industry. The BIO Business Forum® has grown
over the past eleven years to become the industry's largest
partnering event, hosting a record breaking 21,000+ partnering
meetings in 2011. More information can be found at www.bio.org.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company
focused on developing proprietary product candidates. The
Company's lead product candidate is ANX-188, a rheologic,
antithrombotic and cytoprotective agent that improves microvascular
blood flow and has potential application in treating a wide range
of diseases and conditions, such as complications arising from
sickle cell disease. More information can be found on the Company's
web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that are based on ADVENTRX's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding partnering
and networking opportunities at the BIO International Convention
and ANX-188's potential as an effective treatment for patients with
sickle cell disease. Among the factors that could cause or
contribute to material differences between ADVENTRX's actual
results and those indicated from the forward-looking statements are
risks and uncertainties inherent in ADVENTRX's business, including,
but not limited to: the potential for ADVENTRX to delay, reduce or
discontinue current and/or planned development activities, partner
its product candidates at inopportune times or pursue less
expensive but higher-risk development paths if it is unable to
raise sufficient additional capital as needed; ADVENTRX's ability
to obtain additional funding on a timely basis or on acceptable
terms, or at all; the potential for delays in the commencement or
completion of its planned clinical studies including as a result of
difficulties or delays in completing manufacturing process
development activities and manufacturing clinical trial material;
the risk of suspension or termination of a clinical study including
due to lack of adequate funding; the risk that planned clinical
studies of ADVENTRX's product candidates, including ANX-188, are
not successful and, even if they are successful, that the FDA could
determine they are not sufficient to support an NDA for the product
candidate; the risk that the FDA does not grant market approval of
ADVENTRX's product candidates, including ANX-188, on a timely
basis, or at all; ADVENTRX's reliance on third parties to assist in
the conduct of important aspects of its product candidates'
development programs, including the manufacture of clinical trial
material, the conduct of clinical studies and regulatory
submissions related to product approval, and that such third
parties may fail to perform as expected; the risk that intellectual
property protection ADVENTRX obtains with respect to its product
candidates, including ANX-188, is insufficient to provide a
competitive advantage; and other risks and uncertainties more fully
described in ADVENTRX's press releases and periodic filings with
the Securities and Exchange Commission. ADVENTRX's public filings
with the Securities and Exchange Commission are available at
www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
SOURCE ADVENTRX Pharmaceuticals, Inc.